Physician profile
Jerry J Jackson
NPI 1881874584
$4,658.22
in general payments reported to CMS, 2019-2025
27 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $412 · 2021: $624 · 2022: $481 · 2023: $628 · 2024: $1,612 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Travel and Lodging: $1,231 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.81 |
| Travel and Lodging | $1,231.00 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,276.62 | 2024 | Chromophare F300 |
| Viiv Healthcare Company | $1,254.03 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $584.77 | 2019-2025 | |
| Janssen Biotech, INC. | $276.55 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $202.68 | 2021-2024 | Mytesi |
| Emd Serono, INC. | $173.88 | 2019-2023 | Serostim |
| Corcept Therapeutics | $109.51 | 2025 | Korlym |
| Medtronic, INC. | $90.00 | 2021-2023 | Minimed 780g |
| Janssen Products, LP | $79.99 | 2022 | |
| Theratechnologies INC. | $78.67 | 2019-2021 | |
| Amgen INC. | $65.78 | 2021-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $56.40 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.65 | 2019-2020 | |
| Lilly USA, LLC | $48.36 | 2020 | |
| Pfizer INC. | $46.17 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38.10 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $34.97 | 2020 | |
| Insmed, INC. | $32.43 | 2019 | |
| Merck Sharp & Dohme LLC | $24.41 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.44 | 2023 | Quviviq |
| Aimmune Therapeutics, INC. | $18.64 | 2023 | |
| Exact Sciences Corporation | $18.06 | 2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $18.05 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.12 | 2024 | Xifaxan, Trulance |
| Allergan, INC. | $14.62 | 2020 | |
| Becton, Dickinson and Company | $13.21 | 2023 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.